Cas:916975-92-3 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]imidazole manufacturer & supplier

Chemical Name:4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]imidazole

CAS.NO:916975-92-3

Synonyms:4-Methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]-1H-imidazole;T5N CNJ AR CNW EXFFF& D1;1H-Imidazole, 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]-

Molecular Formula:C₁₁H₈F₃N₃O₂

Molecular Weight:271.195

HS Code:2933290090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:362.6±42.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.564

PSA:63.64000

Exact Mass:271.056854

LogP:2.84

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]-1H-imidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Imidazole, 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D1 Use and application,4-Methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]-1H-imidazole technical grade,usp/ep/jp grade.

Related News: Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]imidazole manufacturer J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed. 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]imidazole supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]imidazole vendor Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies. 4-methyl-1-[3-nitro-5-(trifluoromethyl)phenyl]imidazole factory J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed.